Civic AI
Procurement intelligence
Federal contract award
TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES.
REVAGENIX INC · Department of Health and Human Services
- Value
- $26,944,787
- Start
- Jul 1, 2020
- End
- Aug 31, 2026
- Action date
- Jan 26, 2026
- PIID
- 75N93020C00018
- Status
- active
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- SAN DIEGO, CA
- Award type
- DEFINITIVE CONTRACT
Description
TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES.
Need modifications, related awards, and vendor peers? Open the full award workspace.